Nektar Therapeutics (NASDAQ:NKTR) Coverage Initiated at B. Riley

Jan 8, 2025 · B. Riley assumed coverage on shares of Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) in a research note issued to investors on Wednesday, MarketBeat.com …

$4
OFF

Nektar Initiated With A Buy At B. Riley - Nasdaq

2 weeks from now

Jan 8, 2025 · B. Riley last night initiated coverage of Nektar (NKTR) with a Buy rating and $4 price target The firm views Nektar’s most advanced T regulatory cell targeting candidate, …

nasdaq.com

$4
OFF

Nektar Initiated With A Buy At B. Riley - Nasdaq

2 weeks from now

Jan 8, 2025 · B. Riley initiated coverage of Nektar (NKTR) with a Buy rating and $4 price target Stay Ahead of the Market:Discover outperforming stocks and invest smarter with Top Smart …

nasdaq.com

$4
OFF

Nektar Initiated With A Buy At B. Riley | Markets Insider

2 weeks from now

Jan 8, 2025 · B. Riley initiated coverage of Nektar (NKTR) with a Buy rating and $4 price target Discover outperforming stocks and invest smarter with Top Smart Score Stocks Filter, …

businessinsider.com

$4.00
OFF

Nektar Therapeutics (NKTR) Gets A Buy From Piper Sandler

2 weeks from now

6 days ago · In a report released on January 7, B.Riley Financial also initiated coverage with a Buy rating on the stock with a $4.00 price target. See Insiders’ Hot Stocks on TipRanks >>

businessinsider.com

$4.00
OFF

Nektar Stock Positioned For Growth As B. Riley Forecasts REZPEG As …

2 weeks from now

Jan 8, 2025 · On Wednesday, B.Riley initiated coverage on shares of Nektar Therapeutics (NASDAQ: NKTR) with a Buy rating and a price target of $4.00.With the stock currently trading …

investing.com

$4.00
OFF

Nektar Therapeutics (NASDAQ:NKTR) Receives "Buy" Rating

2 weeks from now

3 days ago · B. Riley began coverage on shares of Nektar Therapeutics in a report on Wednesday, January 8th. They issued a "buy" rating and a $4.00 target price on the stock. …

marketbeat.com

400%
OFF

Nektar Therapeutics (NKTR) - Yahoo Finance

2 weeks from now

Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential. Piper Sandler has initiated coverage on Nektar Therapeutics Inc (NASDAQ:NKTR), citing the …

yahoo.com

$7.00
OFF

Zacks Research Has Bullish Estimate For NKTR FY2024 Earnings

2 weeks from now

4 days ago · Piper Sandler initiated coverage on shares of Nektar Therapeutics in a research report on Monday, November 4th. They set an “overweight” rating and a $7.00 target price for …

etfdailynews.com

$4
OFF

B. Riley Securities Initiates Coverage On Nektar Therapeutics With …

2 weeks from now

Jan 8, 2025 · B. Riley Securities analyst Mayank Mamtani initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Buy rating and announces Price Target of $4.

sahmcapital.com

$4.00
OFF

Nektar Stock Positioned For Growth As B. Riley Forecasts REZPEG As …

2 weeks from now

Jan 8, 2025 · On Wednesday, B.Riley initiated coverage on shares of Nektar Therapeutics (NASDAQ: NKTR) with a Buy rating and a price target of $4.00.With the stock currently trading …

investing.com

$4.08
OFF

Nektar Therapeutics (NASDAQ:NKTR) Stock Rating Upgraded By B.

2 weeks from now

Jan 9, 2025 · According to MarketBeat, Nektar Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $4.08. Read Our Latest Report on NKTR …

marketbeat.com

FAQs about Nektar Therapeutics (NASDAQ:NKTR) Coverage Initiated at B. Riley Coupon?

Should you buy Nektar Therapeutics (NKTR)?

Fintel reports that on January 8, 2025, B. Riley Securities initiated coverage of Nektar Therapeutics (NasdaqCM:NKTR) with a Buy recommendation. Analyst Price Forecast Suggests 302.86% Upside As of December 23, 2024, the average one-year price target for Nektar Therapeutics is $4.79/share. The forecasts range from a low of $1.31 to a high of $7.35. ...

What is the average price target for Nektar Therapeutics (Nektar)?

As of December 23, 2024, the average one-year price target for Nektar Therapeutics is $4.79/share. The forecasts range from a low of $1.31 to a high of $7.35. The average price target represents an increase of 302.86% from its latest reported closing price of $1.19 / share. See our leaderboard of companies with the largest price target upside. ...

How do I receive news & ratings for Nektar Therapeutics?

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter. ...

How many funds own Nektar Therapeutics (NKTR)?

There are 264 funds or institutions reporting positions in Nektar Therapeutics. This is an increase of 50 owner (s) or 23.36% in the last quarter. Average portfolio weight of all funds dedicated to NKTR is 0.04%, an increase of 7.78%. Total shares owned by institutions increased in the last three months by 9.26% to 168,130K shares. ...

Who owns Nektar Therapeutics?

Nantahala Capital Management LLC now owns 4,110,000 shares of the biopharmaceutical company’s stock worth $5,096,000 after acquiring an additional 1,634,046 shares during the last quarter. Samlyn Capital LLC acquired a new position in shares of Nektar Therapeutics in the 2nd quarter worth approximately $11,728,000. ...

Does Nektar Therapeutics (NKTR) have a cash runway in 2026?

Nektar Therapeutics (NKTR) extends its cash runway into 2026 with strategic divestitures, despite ongoing financial challenges and litigation uncertainties. Nektar (NKTR) delivered earnings and revenue surprises of 21.74% and 55.24%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? ...